Merck KGaA (XSWX:MER) ROE % Adjusted to Book Value: 5.76% (As of Mar. 2026)

Merck KGaA XSWX:MER +4.03% 83 ROE % Adjusted to Book Value is 5.76% as of Mar. 2026. GuruFocus rates XSWX:MER with a GF Score™ of 83/100 and a GF Value™ of CHF125.76. The stock has 9 warning signs investors should review.

Merck KGaA's ROE % for the quarter that ended in Mar. 2026 was 8.93%. Merck KGaA's PB Ratio for the quarter that ended in Mar. 2026 was 1.55. Merck KGaA's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 5.76%.

Merck KGaA ROE % Adjusted to Book Value Related Terms

Merck KGaA ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Merck KGaA's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck KGaA ROE % Adjusted to Book Value Chart

Merck KGaA Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

3.64

3.63

0.00

Merck KGaA Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	5.76

XSWX:MER vs ZTS, UTHR, VTRS: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Merck KGaA's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Merck KGaA ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck KGaA's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Merck KGaA's ROE % Adjusted to Book Value falls into.

Save Embed

83GF Score

Merck KGaA XSWX:MER

ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Merck KGaA ROE % Adjusted to Book Value Calculation

Merck KGaA's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	8.91%	/	N/A
	=	N/A

Merck KGaA's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	8.93%	/	1.55
	=	5.76%

Frequently Asked Questions Learn more about ROE % Adjusted to Book Value →

What does a ROE % Adjusted to Book Value of 5.76% mean?

Merck KGaA (XSWX:MER) has a ROE % Adjusted to Book Value of 5.76% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Merck KGaA and its competitors.

Is Merck KGaA's ROE % Adjusted to Book Value too high?

Merck KGaA's current ROE % Adjusted to Book Value is 5.76%. Overall, Merck KGaA has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.

How does Merck KGaA's ROE % Adjusted to Book Value compare to ZTS and UTHR?

Merck KGaA's ROE % Adjusted to Book Value of 5.76% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?

A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROE % Adjusted to Book Value mean?

A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Merck KGaA and its competitors. Merck KGaA's current ROE % Adjusted to Book Value is 5.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Merck KGaA stock overvalued right now?

Merck KGaA (XSWX:MER) has a current ROE % Adjusted to Book Value of 5.76%. The stock's GF Value™ is CHF125.76, compared to a current price of CHF130.30 — trading 3.6% above its estimated fair value. The current ROE % Adjusted to Book Value is 5.76%. Merck KGaA's overall GF Score™ is 83/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROE % Adjusted to Book Value calculated?

ROE % Adjusted to Book Value is calculated from a company's financial statements. For Merck KGaA (XSWX:MER), the current ROE % Adjusted to Book Value is 5.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck KGaA (XSWX:MER) Overvalued in 2026?

Based on GuruFocus' analysis, Merck KGaA stock appears to be overvalued. The current stock price of CHF130.30 is trading 3.6% above its estimated GF Value™ of CHF125.76.

Key valuation signals for XSWX:MER:

ROE % Adjusted to Book Value: 5.76%
GF Value™: CHF125.76 vs. price of CHF130.30 (3.6% above fair value)
GF Score™: 83/100 with 9 warning signs

No single metric tells the full story. See the XSWX:MER stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Merck KGaA Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies XTER:EVT XTER:B8FK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR HKSE:03692 VTRS NSE:DIVISLAB OSTO:SOBI NBIX NSE:TORNTPHARM SHSE:688506 XPAR:IPN TSE:4507

Other Exchanges MKKGY:USA MKGAF:USA 1MRK:Italy MRKd:UK 0O14:UK MRK:Germany MRCK:Austria

Address Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293

Website https://www.merckgroup.com

Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.

83GF Score

Get the complete analysis for XSWX:MER

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF130.30

Price

CHF125.76

GF Value

View XSWX:MER Analysis

See ROE % Adjusted to Book Value data for all stocks →